Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the symbol lookup tool.
Alphabetize the sort order of my symbols
Company Description (as filed with the SEC)
We are a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ® (lorcaserin HCl), our internally discovered drug for chronic weight management, is our first and only drug approved by any regulatory agency for marketing. BELVIQ was approved by the US Food and Drug Administration, or FDA, for marketing in the United States, and was made available by prescription in June 2013 to adults who are overweight with a comorbidity or obese. As described below, there are pending applications for the regulatory approval of BELVIQ for marketing in a number of additional counties under our collaborations. In addition to BELVIQ, we have drug candidates and compounds at various stages of research and development. The key elements of our strategy are as follows: • Make BELVIQ Available to Patients for Chronic Weight Management. ... More ...
|Annual EPS Est:||$-0.09|
|Quarterly EPS Est:||-0.1|